Literature DB >> 7709951

Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus.

J S Ginsberg1, C Demers, P Brill-Edwards, R Bona, M Johnston, A Wong, J A Denburg.   

Abstract

In order to determine whether there is a relationship between acquired free protein S deficiency and increased thrombin generation, we performed a cross-sectional study of patients with systemic lupus erythematosus (SLE). Plasma samples were assayed for free protein S and were correlated to levels of prothrombin fragments (F1 + 2); an elevated level of F1 + 2 was used as a surrogate marker for a prothrombotic state. Assays for anticardiolipin antibodies (ACA) and lupus anticoagulant (LA) were performed on two separate blood samples taken at least 3 months apart in order to detect the presence of antiphospholipid antibodies. Of the 36 subjects, 9 had reduced free protein S levels compared to 0 of 21 controls (P = 0.01) and the mean free protein S level was significantly lower in the SLE population than in controls (0.30 +/- 0.08 U/mL versus 0.43 +/- 0.10 U/mL, P < 0.001). Of the 24 subjects with antiphospholipid antibodies, 9 had reduced free protein S levels, compared to 0 of 12 subjects without antiphospholipid antibodies (P = .01). The mean F1 + 2 level was significantly higher in study subjects with reduced free protein S levels than in those with normal free protein S levels (1.22 +/- 0.50 nmol/L versus 0.78 +/- 0.27 nmol/L, P = 0.05). This study confirms an association between antiphospholipid antibodies and reduced free protein S levels and demonstrates that patients with SLE and acquired free protein S deficiency generate more thrombin than patients with SLE and normal free protein S levels. Further studies are needed to determine whether the thrombotic diathesis associated with the presence of antiphospholipid antibodies is directly caused by the concomitant presence of acquired free protein S deficiency.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7709951     DOI: 10.1016/S0002-9343(99)80317-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  12 in total

Review 1.  Clinical trials for the antiphospholipid syndrome.

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

Review 2.  The antiphospholipid syndrome and atherosclerosis: clue to pathogenesis.

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

3.  Autoimmune diseases and venous thromboembolism: a review of the literature.

Authors:  Bengt Zöller; Xinjun Li; Jan Sundquist; Kristina Sundquist
Journal:  Am J Cardiovasc Dis       Date:  2012-07-25

Review 4.  What causes the antiphospholipid syndrome?

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

5.  Anti-human protein S antibody induces tissue factor expression through a direct interaction with platelet phosphofructokinase.

Authors:  Changyi Chen; Dan Liao; Jing Wang; Zhengdong Liang; Qizhi Yao
Journal:  Thromb Res       Date:  2013-11-16       Impact factor: 3.944

6.  Antiphospholipid syndrome presenting as pulmonary thrombosis and pancreatitis in a young man.

Authors:  Sanat Phatak; Neelam Redkar; Meenakshi Amit Patil; Niteen D Karnik
Journal:  BMJ Case Rep       Date:  2012-12-12

7.  TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus.

Authors:  Chang-Hee Suh; Brendan Hilliard; Sophia Li; Joan T Merrill; Philip L Cohen
Journal:  Arthritis Res Ther       Date:  2010-07-16       Impact factor: 5.156

8.  The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies.

Authors:  Marie Hudson; Andrée-Laure Herr; Joyce Rauch; Carolyn Neville; Erika Chang; Reda Ibrahim; Chantal Séguin; Jeannine Kassis; Lambert Busque; Paul R Fortin
Journal:  J Rheumatol       Date:  2003-11       Impact factor: 4.666

9.  Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system.

Authors:  T Atsumi; M A Khamashta; O Amengual; S Donohoe; I Mackie; K Ichikawa; T Koike; G R Hughes
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

Review 10.  TAM receptor tyrosine kinase function and the immunopathology of liver disease.

Authors:  S K Mukherjee; A Wilhelm; C G Antoniades
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-02-11       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.